Skip to main content
. 2022 Feb 7;322(3):E307–E318. doi: 10.1152/ajpendo.00234.2021

Figure 2.

Figure 2.

Sacubitril does not increase oral GSIS or circulating active GLP-1 levels in anesthetized mice. Plasma glucose (A) and insulin (C) levels during an OGTT at the end of the 8-wk treatment period in VEH-CTL (open circles, n = 13), STZ-CTL (black circles, n = 18), and STZ-SAC (gray triangles, n = 17) groups of anesthetized male Glp1r+/+ mice. Calculated incremental areas under the curve (iAUC) for glucose (B), insulin (D), and insulin/glucose (E) from 0–30’ and 0–120’ during the OGTT. F: active GLP-1 levels measured during the OGTT, 10 min after glucose administration. *P ≤ 0.05 (analyzed using one-way ANOVA followed by Dunnet’s multiple comparisons test). Data are means ± SE. CTL, control; GLP-1, glucagon-like peptide-1; HFD: high-fat diet; OGTT, oral glucose tolerance test; SAC, sacubitril; STZ, streptozotocin; VEH, vehicle.